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Abstract
Background: Greater trochanteric pain syndrome (GTPS) is pathology in the gluteus medius and minimus tendons
and trochanteric bursa that causes debilitating tendon pain and dysfunction, particularly in post-menopausal
women. Limited evidence in clinical studies suggests hormone changes after menopause may have a negative
effect on tendon. This protocol describes a randomised controlled trial comparing the effectiveness of menopausal
hormone therapy (MHT) and exercise therapy in reducing pain and dysfunction associated with GTPS in
post-menopausal women.
Method: One hundred and sixteen post-menopausal women will be recruited and randomised to receive one of
two exercise programs (sham or targeted intervention exercise) and transdermal creams (MHT cream containing
oestradiol 50mcg and norethisterone acetate 140mcg or placebo cream). Interventions will be 12-weeks in duration
and outcomes will be examined at baseline, 12-weeks and 52-weeks. The primary outcome measure will be the
VISA-G questionnaire and secondary outcomes measures will include three hip pain and function questionnaires
(Hip dysfunction and Osteoarthritis Outcome Score, Oxford Hip Score, Lateral Hip Pain questionnaire), a global
change in symptom questionnaire (using a 15-point Likert scale) and a quality of life measure (AQoL-8D
questionnaire). Data will be analysed using the intention to treat principle.
Discussion: This study is the first randomised controlled trial to compare the effectiveness of menopausal hormone
therapy therapy alone, and with the combination of exercise therapy, to treat pain and dysfunction associated with
GTPS. This study has been pragmatically designed to ensure that the interventions in this study can be integrated
into policy and clinical practice if found to be effective in the treatment of GTPS in post-menopausal women. If
successful, there is potential for this treatment regimen to be explored in future studies of other persistent tendon
conditions in the post-menopausal population.
Trial registration: Australian New Zealand Clinical Trials Registry ACTRN12614001157662 Registered 31 October 2014.
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Background
Greater trochanteric pain syndrome (GTPS) is an over-
arching term used to describe a degenerative condition of
the gluteus medius and minimus tendons (gluteal tendino-
pathy) and trochanteric bursa (trochanteric bursitis). The
condition is characterised by intermittent or continuous
pain at, or around, the greater trochanter of the femur [1],
often with long-term pain and disability. Greater trochan-
teric pain syndrome most commonly affects post-
menopausal women between 45 and 63 years old [2] and
is severely debilitating, resulting in limited activity, quality
of life, employment and capacity to exercise. The reported
incidence of GTPS is 1.8 per 1000 patients per year in pri-
mary care [2] and prevalence rates of 23.5 % in women at
risk of knee osteoarthritis [3] and 54 % in recipients of
renal transplants [4]. These statistics likely underestimate
the prevalence of GTPS since misdiagnosis and lack of
recognition of GTPS are common.
The increased prevalence of GTPS in post-menopausal
women [2] suggests that deficits in female sex hormone
may be implicated in the condition. A number of risk
factors for tendinopathy are associated with levels of cir-
culating female sex hormones - advancing age, female
gender and body composition [5, 6]. In pre-menopausal
women, the likelihood of developing lower limb tendino-
pathy is lower than that of age matched men [7]. In post-
menopausal women, as oestrogen levels decline, collagen
production declines, tendon becomes thinner [8] and rates
of tendon pathology and the likelihood of tendon rupture
increases [9]. It is known that supplemental oestrogen is
beneficial for increasing skeletal muscle strength [10],
reducing fractures [11], preserving bone mass [12] and
preventing a decline in the collagen content of skin [13].
It is feasible that supplemental oestrogen in the post-
menopausal population may also preserve tendon collagen
[8] and decrease tendon abnormality [6].
Despite this theory, current knowledge of the physio-
logical effect of female sex hormone on tendon is limited
[14–16], with some evidence of increased type 1 collagen
upregulation and turnover [17–19], increased fibroblast
proliferation [20, 21] and inhibition of pro-inflammatory
cytokines [18, 22]. Animal studies also point to the
upregulation of relaxin receptors and a resultant effect on
the extracellular matrix of the tendon [23], however
the literature is limited, inconsistent and generally of
poor quality. A small number of observational studies
[6, 17, 19, 22, 24–26] and one poorly designed rando-
mised controlled crossover study [18] have investigated
the effects of hormone therapy on the Achilles and patel-
lar tendon. None of these studies examined patient re-
ported outcome measures (pain, function, quality of life)
to evaluate the effects of such interventions. As yet, there
are no studies looking at the effects of menopausal hor-
mone therapy (MHT) on gluteal tendon and no rigorous
prospective RCT’s have been published in any other ten-
don. In addition, the optimal dosage, duration and method
of administration of MHT to affect molecular, mechanical,
and morphological tendon outcomes are unknown.
Traditionally, physiotherapy and exercise are first line
interventions in the clinical management of tendinopathy
[27–32] with any form of injection (e.g. cortisone,
platelet rich plasma or autologous blood) and opera-
tive interventions offered subsequent to conservative
tendon management [33, 34]. However, for gluteal
tendon conditions, an abundance of research exists
for both injection and operative methods and little
exists for conservative treatment options [35]. If like
other lower limb tendons, the gluteal tendons are re-
sponsive to load, then a similar treatment algorithm
used in that of the patellar and Achilles tendon [36],
should be effective in reducing pain and dysfunction.
The most recent systematic review on the effects of
treatment of gluteal tendinopathy concluded that there
was a need to conduct further randomised controlled
trials [35]. Treatment interventions investigated included
shockwave therapy, ‘home training’, corticosteroid injec-
tions and operative procedures (arthroscopic and open
bursectomy, ilio-tibial band release, open bursectomy,
tendon reattachment, trochanteric reduction osteotomy
and endoscopic repair of gluteus medius tears). Only 1
out of the 14 included studies used exercise as an inter-
vention [37]. Rompe et al. [37] compared a home train-
ing program involving progressive slow repetitive
exercise (piriformis and ilio-tibial band stretching,
straight leg raise, wall squat with ball and gluteal
strengthening) with shock wave therapy and corticoster-
oid injection [37]. Exercise therapy was found to be less
superior to corticosteroid injection at 1 month follow up
but more superior at the 15 month follow up, indicating
the longer-term benefits of exercise therapy. This re-
sponse is similar to that seen in other tendons [38–40].
This review demonstrates that the role of exercise
therapy in the management of greater trochanteric pain
syndrome needs further investigation.
The proposed study will investigate two feasible man-
agement options for post-menopausal women with GTPS
- hormone supplementation and exercise. The aim of this
study is to investigate the effect of menopausal hormone
therapy and exercise on pain and function in post-
menopausal women with GTPS. We hypothesise that sup-
plemental hormones and exercise may be beneficial for re-
ducing pain and dysfunction measured by a clinical
significant change in VISA-G scores and a significant im-
provement in quality of life measures. If successful, there
is potential for this treatment regimen to be explored in
future studies of other persistent tendon conditions such
as Achilles, rotator cuff and lateral elbow tendinopathy in
the post-menopausal population.
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Methods
The trial has been registered on the Australian New
Zealand Clinical Trials Registry (ACTRN12614001157662)
and has a Universal Trial Number (U1111-1160-2743).
Protocol modifications will be approved by the ethics com-
mittee and communicated via the ANZCTR.
Ethical approval and consent
The trial has received ethical approval from the La Trobe
University Human Ethics Committee (number 14-055).
Prior to enrolment, all participants will provide written
informed consent to participate in the study, and for
the publication of this manuscript (Additional file 1).
Ethical standards will adhere to the National Health
and Medical Research Council (NHMRC) National
Statement [43] and the World Medical Association’s
Declaration of Helsinki [44].
Design
This study is a randomised 2 x 2 factorial trial with a 12-
week intervention period and outcomes measured at
baseline, 12-weeks and 52-weeks (Fig. 1). Reporting of
Fig. 1 Gluteal La Trobe Trial (GLoBE) Profile
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this study will be formatted according to the Consoli-
dated Standards of Reporting Trials (CONSORT) 2010
statement [45, 46] and incorporates the Standard




Post-menopausal women with GTPS will be recruited
through medical practitioners and healthcare profes-
sionals. Further advertising on community noticeboards,
social media, Melbourne radio, newspapers and the
Gumtree advertising service will also be conducted.
Interested volunteers will contact the chief investiga-




Potential participants will initially be screened via tele-
phone to exclude those with obvious medical risk factors
to MHT (Table 1). Further exclusion is warranted if the
potential participant has received hormone therapy sup-
plementation or invasive procedures (including injection)
around the hip in the previous 12 weeks. If no obvious
exclusion criteria exist, the participant will be referred
for medical assessment.
Medical assessment
Participants found to be eligible after the phone screen-
ing will be invited to attend a medical examination by a
sports physician. Upon presentation to their medical
examination, participants will again be educated on the
nature of the trial and asked to provide informed con-
sent. Potential participants will be advised at that point
that inclusion in the trial is on the provision that their
medical history, clinical examination, blood samples and
electrocardiograph (ECG) meet inclusion criteria.
The medical consultation will involve a full medical
history to determine risk factors that would contraindi-
cate the use hormone supplementation, and perform a
clinical examination for the presence of greater trochan-
teric pain. Medical history will detail the history of present-
ing condition, family history, past medical history, social
history (demographics, occupation, and recreation/activity
participation), medication usage, substance use/abuse
(alcohol, recreational drugs, smoker status) and allergies.
Clinical assessment to assess GTPS will involve five
clinical pain provocation tests. Tests will include the
Trendelenburg test [41], palpation of the greater trochan-
ter [42], the Patrick-Faber test [43], resisted external de-
rotation test [41] and modified external de-rotation test
(increased hip adduction moment). Participants are asked
if testing reproduces reported symptoms or pain, the
location of the symptoms and intensity of pain on a 0–10
Visual Analogue Scale (VAS). A positive test is defined as
a spontaneous reproduction of the participant’s lateral hip
pain. To be eligible for the trial, clinical testing must re-
produce pain in 3 of 5 pain provocation tests.
Where a participant meets inclusion criteria and has
not had a platelet-rich plasma (PRP), analogous blood
injection (ABI) or corticosteroid injection in the hip
region in the last 3 months, but is excluded from the
hormone intervention on medical grounds, they will
be randomised into a single arm (intervention exercise or
sham exercise).
Blood sampling and electrocardiography
Participants who remain eligible for the study following
medical consult, will be referred for blood tests and an
electrocardiograph to confirm eligibility in the trial.
Blood tests will examine lipid levels (fasting cholesterol,
triglycerides, high density lipoprotein: HDL, low density
lipoprotein: LDL), liver function (LFT), diabetes indicators
(glucose, HbA1c), iron (Fe) studies and thyroid function
(TFT). Serum levels of follicle stimulating hormone (FSH)
Table 1 Eligibility criteria
Inclusion Criteria Exclusion Criteria
• Post-menopausal women, >52 weeks of amenorrhea and a serum
oestradiol of 0-120pmol/L and an FSH of >20 IU/L
• Lateral hip pain reproduction in 3 of 5 pain provocation tests
(Trendelenburg test, palpation of the greater trochanter, FABER, resisted
external derotation test, modified resisted external derotation test)
• Have sufficient English skills to be able to read and understand the
information and consent form due to the risks involved with participating
in the study.
• Known adverse reaction to any form of hormone therapy
• Use of any form of female hormone supplementation within the last
12 weeks
• Display high risk factors for deep vein thrombosis (DVT) using the
Wells score system [85] and/or pulmonary embolism (PE).
• Current smoker
• History of stroke, severe menstrual migraine, endometrial sarcoma,
breast cancer, severe hyperlipidaemia, chronic liver disease, thyroid
disease, lupus, hysterectomy and oophorectomy
• HbA1c >8 %
• Current cholecystitis, fibroids or undiagnosed abnormal uterine bleeding
• Platelet-rich plasma (PRP), analogous blood injection (ABI) or
corticosteroid injection into the hip region in the last 12 weeks
• History of hip trauma or surgery on the affected side
• Any other musculoskeletal, neurological and cardiorespiratory
condition/s affecting their ability to participate in the study.
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and oestradiol will also be recorded as a baseline measure
and compared to levels post pharmacological intervention.
A 12 lead echocardiograph (ECG) will be undertaken to
monitor if any arrhythmia or irregularities are present.
Indicators for inclusion or exclusion of a participant
will be made on clinical judgement by the treating
physician, taking into account all individual tests results
and their normative values.
Once deemed eligible for the trial, participants will be
randomly allocated into an exercise group and a trans-
dermal cream group. A participant may be randomised
into one of the following 12-week interventions: (i) exer-
cise therapy, placebo cream; (ii) sham exercise, MHT
cream; (iii) sham exercise, placebo cream or (iv) exercise
therapy, MHT cream.
Sample size and power analysis
The sample size required for this RCT is 100 partici-
pants (25 in each group) to detect a minimal clinically
important difference of 10 points on the VISA-G out-
come measure, assuming a standard deviation of 13
(Alpha of 0.05 and a power of 80 %) [44]. To account
for potential drop-out, we will recruit 116 participants
(29 per group).
Randomisation, allocation and blinding
A block randomisation schedule will be generated using
a web based randomisation program (https://www.ran-
domizer.org/) with the sequence tranferred onto a com-
puter spreadsheet by a researcher external to the trial
investigators, who will have no contact with participants
throughout the duration of the trial. This external re-
searcher will complete concealed allocation of participants
to groups in accordance with the randomisation schedule.
All data collected will be de-identified and only made ac-
cessible to the study investigators.
Participants will be blinded to allocation for both the
exercise therapy and hormone therapy group. Placebo
creams and sham exercise groups, may increase the suc-
cess of participant blinding [46]. The success of blinding
will be formally measured during week 1 of the trial by
asking participants to indicate which group for both
interventions they believe they are allocated to. It is
important to assess the success of blinding to determine
if protection against participant expectation effects is
maintained [46]. The treating physiotherapists will be
blind to cream type, but due to the nature of the inter-
vention, cannot be blinded to exercise group. Detailed
training of physiotherapists will be provided to ensure
equivalent provision of care and motivation for both
groups [47]. Unblinding of a participant and trial investi-
gators to cream allocation will only be permissable in
the unlikely event of an adverse reaction requiring medical
team involvement.
Data analysts and outcome measure assessors will be
blinded to group allocation. This will be achieved
through direct communication from the external re-
searcher preparing the randomisation schedule to the
trial physiotherapist implementing the exercise interven-
tion and the pharmacist implementing the hormone
cream intervention.
Interventions
All participants will be educated on the nature of their
pathology, the rationale for exercise treatment, the im-
portance of adherence to their home program as well as
activities to avoid (ascending and descending stairs, sit-
ting in low chairs, lying on hip during sleep). They will
be provided an information booklet that includes this in-
formation. The booklet details pain relieving postural
strategies (standing, sitting and lying/sleeping) to adopt
during the 12-week intervention. Participants may apply
an ice pack to the lateral hip region at any time; are
encouraged to stay active within their pain limits and to
continue their normal pain medication regime during the
12-week intervention. Both medication use and ice applica-
tion will be recorded throughout the trial in the partici-
pant’s exercise/transdermal cream application diary. All
participants are able to continue normal daily activities but
will be asked to identify any medication usage for their ten-
dinopathy (e.g. NSAIDs) and cease any other physical
treatment (physiotherapy, etc.).
Exercise therapy
Both exercise therapy groups will complete a 12-week
exercise program prescribed by a physiotherapist. Partici-
pants in both groups will attend a physiotherapy consult-
ation at baseline, 4-weeks, 8-weeks and 12-weeks post
randomisation for progression of their exercise program
and monitoring of adherence. A booklet that features pho-
tos and explanations of each exercise will be given to each
participant for further reference and participants are in-
vited to contact their physiotherapist at any time during
the 12 week intervention if they have queries about their
cream or exercise program. Before, during and after the
12 week program, participants are invited to contact the
researchers with any questions about the trial. Two cycles
of the exercise program will be completed twice daily
(AM and PM). Both programs should take approximately
15 min to complete.
Gluteal La Trobe trial (GLoBE) protocol/intervention exercise
therapy
Participants randomised into the intervention exercise
group will be instructed in the GLoBE protocol, a gluteal
tendon exercise program designed by clinicians who are
expert in treating tendon pathology. Although numerous
rehabilitation exercises (eccentric [32, 48], concentric
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[30, 49] and isometric [50]) have been described for the
management of Achilles and patellar tendinopathy, there
is little evidence on effective exercise therapy in the re-
habilitation of GTPS [37]. There is evidence that the use
of isometric exercises may reduce tendon pain in the ini-
tial stages of rehabilitation [50] and allow the continuation
of sporting activities [51]. This pain relief may provide a
window of opportunity for lower limb strengthening with
isotonic exercise. The effectiveness of isometric exercises
is yet to be validated in the GTPS population. The GLoBE
protocol largely focuses on isometric loading of the
gluteus medius and minimus, and strengthening of the
kinetic chain – quadriceps and calf muscle groups. It is a
graduated exercise program where participants are able to
progress through the stages in each subsection of gluteal,
quadriceps and calf strengthening. The gluteal strengthen-
ing commences with a hip hitch in standing, whereby the
participant, holding onto a wall or chair for balance,
hitches their unaffected leg up off the ground (approxi-
mately 1 cm) whilst keeping their knee in full extension,
causing the contralateral/affected gluteal tendons to be
loaded out of a compressed position. This hip hitch is then
integrated into dynamic exercises by adding a toe taps or
hip swings as progressions. The most advanced exercise in
the gluteal series, is a single leg wall squat. Quadriceps
strengthening commences with a double leg ¼ squat and
progresses to a ½ squat, sit to stand exercise and
then to step ups. Calf strengthening involves double
leg calf raises, calf raises with toe taps and progresses
onto single leg calf raises.
Sham exercise program
The control group will receive a sham exercise program
not suitable for the rehabilitation of gluteal tendons,
instructed by a physiotherapist. Like the GLoBE protocol,
the program is completed as a cyclic three-stage approach,
where participants are able to progress through each sub-
section of sham gluteal, quadriceps and calf strengthening.
The sham program involves exercises for the kinetic chain
in an unloaded environment (sitting) and thus, does not
therapeutically load the gluteal tendons.
Physiotherapy treatment integrity
A variety of methods will be used to ensure the integrity
of the exercise intervention is maintained. All treating
physiotherapists will have a minimum of 2 years clinical
experience in private musculoskeletal physiotherapy
practice and will undertake a compulsory 1 day training
course. This will incorporate extensive education about
GTPS, a step-by-step approach to the two exercise inter-
ventions and guidelines on trial reporting (participant
adherence, adverse events, and clinical note taking). The
education session will include group discussions and
portions of experiential learning such as patient role play
and formal clinical mentoring as outlined by Main et al.,
[47] for training physiotherapists delivering interventions.
Regular phone and email contact with the researchers and
provision of a comprehensive treatment manual will aim
to maximise therapist adherence to the protocol. Add-
itionally, a large emphasis will be placed on the import-
ance of equal service provision and standardisation of
enthusiasm of both exercise protocols [52, 53].
Physiotherapists will use structured electronic record-
ing forms for sham and intervention exercise programs.
These will include a series of check boxes to prompt the
clinician through each stage of the program and to ensure
standardisation of treatment intervention. Additionally,
the physiotherapist will be instructed to record exercises
prescribed, adherence, use of pain or NSAID medications
and/or ice application and any adverse events. These mea-
sures adhere to the recommended requirements for ensur-
ing treatment fidelity [47]. Clinical notes will be audited
by research staff at 4-weeks and 12-weeks to ensure that
all documentation is standardised, legible and complete.
Transdermal cream
All participants will be required to apply 1 g of the com-
pounded transdermal cream daily to thin-skin areas of
the body to aid absorption and rapid distribution of ac-
tive ingredients. Cream application sites will be rotated
every 5 days – alternating between the inner right wrist
and the inner left wrist. Rotation of sites every 5 days
will reduce the likelihood of up-regulation of receptors
[54]; skin sensitivity by constant application to the same
area and undesired build-up and delayed uptake of ac-
tive ingredients [55]. Participants will be advised to not
to rub in too hard, but simply to spread the gel over the
skin as thinly as possibly to optimise absorption [56].
Both the placebo and intervention transdermal creams
will be applied using a metered dose pump dispenser
manufactured by Medisca, a Therapeutic Goods Adminis-
tration (TGA) registered supplier of pharmacy compound-
ing products. This dispenser accurately delivers the
required dose (1 ml) in one pump (mean error = 0.056 ml,
relative SD = 4.4 %) [57]. Both intervention and placebo
groups will receive an identical instruction sheet for the
application of the cream. The method of application will
also be reinforced verbally by the physiotherapist in the
first exercise treatment session. Any significant or severe
adverse reactions will immediately be referred to a medical
practitioner or emergency department for assessment.
Menopausal hormone therapy transdermal cream
The MHT cream is based on the active ingredients used
in the Estalis Continuous transdermal patch [58]. Cream
application will involve transdermal delivery of supple-
mentary oestradiol (50mcg) and norethindrone acetate
(NETA) (140mcg), a progestin, in a VersaBase® for
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12 weeks in duration. This is likely to increase serum
levels of E2, with an aim to reach an optimum level of
295–550pmol/L [54]. The progestin component provides
essential protection of the uterus to reduce the risk of
endometrial hyperplasia [59].
Placebo transdermal cream
The placebo transdermal cream, applied for a duration
of 12 weeks, will be an inert aqueous transdermal cream
that is identical in colour, texture and consistency to that
of the MHT cream but without the active ingredients.
Baseline assessments
At baseline, a thorough medical history will be taken,
time-interval since menopause documented and current
medication use and dosage will be recorded. Height and
weight will be measured using a stadiometer and digital
scales, respectively, and body mass index will be calcu-
lated as weight (kg)/height (m)2. In addition, six ques-
tionnaires will be administered to monitor pain, function
and quality of life.
Outcome measures
Primary outcome measures
The primary outcome measure will be the VISA-G ques-
tionnaire, a gluteal tendon outcome measure that quan-
tifies pain with tendon loading, with a higher score
representing less pain and dysfunction. This question-
naire contains a visual analogue score for pain, four
questions related to pain, one question related to diffi-
culty with moving after sitting and two activity related
questions [60]. The VISA-G was found to have a test re-
test reliability of ICC2,1 (95 % CI) of 0.83 (0.64 to 0.78)
[60]. Internal consistency was high with a Cronbach’s
Alpha of 0.81. Construct validity was demonstrated: the
VISA-G measures different constructs than both the
Harris Hip Score (HHS) [61] and the Oswestry Disability
Index (ODI) [62] (Spearmans rho: 0.02 and 0.02 respect-
ively). The VISA-G did not demonstrate any floor or
ceiling effect in symptomatic participants. In the current
study, the VISA-G will be documented at baseline, 12-
weeks and 52-weeks.
Secondary outcome measures
Secondary outcome measures will include five question-
naires to assess pain and dysfunction. The following
questionnaires will be administered at baseline, 12-
weeks and 52-weeks: Oxford Hip Score (OHS) [63], glo-
bal rating of change questionnaire, Assessment of Qual-
ity of Life (AQoL), Hip dysfunction and Osteoarthritis
Outcome Score (HOOS) [64] and the Lateral hip Pain
Questionnaire (unpublished, University of Queensland,
Australia).
Failure to improve
Participants will be offered cross over to both active inter-
ventions if their global rating of change score is below 0
(worsened symptoms) at 12 weeks. If in GLoBE exercise
and placebo cream, they will cross over to intervention
cream and continue GLoBE exercise. If in sham exercise
and placebo cream, they will cross over to GLoBE exercise
and intervention cream, if in sham exercise and interven-
tion cream, they will cross over to GLoBE exercise and
continue intervention cream once cleared to do so by
study medical practitioners. Results for this group will be
analysed and presented separately.
Trial follow-up
At 52-weeks, participants will be asked to complete the
six questionnaires again, and asked to specify if they con-
tinued any hormone therapy interventions or had any
form of injection (cortisone, protein-rich-plasma or au-
tologous blood injections) or surgical procedure post-trial.
Success of blinding
To assess the effectiveness of blinding and to ensure
participant expectation effects were protected, partici-
pants will be asked at one-week post intervention if they
know which group they have been randomised to with
the following two questions: “This trial compares the ef-
fect of two exercise programs, a new program and a
standard program. Are you aware of which exercise pro-
gram you received?”; “This trial compares the effect of
two transdermal creams, a hormone therapy cream and
a placebo cream. Are you aware of which transdermal
cream you have received?” For both questions, the par-
ticipant can answer with “yes”, “no” or “unsure”. If the
participant answers “yes” the participant will be further
questioned “which exercise program/cream do you think
you received?” and “why” [46].
Adverse events
Complications and adverse events associated with the
intervention are unlikely, however, minor, significant and
severe adverse events for this trial are based on the
MIMS Australia Estalis Continuous (oestradiol/NETA:
norethisterone acetate) consumer information sheet
[58]. All adverse events will be recorded in the clinical
notes, significant events referred to the treating medical
practitioners and severe events referred to the emer-
gency department. Significant and severe adverse events
will be reported to the La Trobe University Human
Ethics Committee, Faculty of Health Sciences using a
standardised form. A participant has the right to withdraw
from the study at any time.
Minor Adverse Event: Refers to any symptom or event
reported by the participant that may be potentially re-
lated to the intervention. This will include:
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 irregular vaginal bleeding or spotting
 tender, painful or swollen breasts
 menstruation-like pain
 redness, irritation or itching at the site/s of cream
application
 skin rash
 vaginal itching, inflammation or fluid discharge
 swelling of the lower legs, ankles, fingers or
abdomen due to fluid retention
 nausea, abdominal cramps, vomiting, heartburn,
wind, diarrhoea
 headache, migraine
 rise in blood pressure
 weakness or dizziness
 depression, nervousness, rapid changes in mood,
difficulty sleeping
 back pain
 change in sex drive
 weight gain
 acne, itchy or dry skin, skin discolouration
 darkening of the skin particularly on the face or
abdomen (chloasma)
 hair loss
Significant Adverse Event: Any symptom or event po-
tentially related to the intervention that interrupts the
participant’s ability to continue with the RCT interven-
tion, or requires the participant to be referred to a med-
ical practitioner. This will include:
 heavy vaginal bleeding
 pain or tenderness in the abdomen, which may be
accompanied by fever, loss of appetite, nausea and
vomiting
 a yellow colour to the skin or eyes, itching,
dark coloured urine or light coloured bowel
motions
Severe Adverse Event: Any symptom or event potentially
related to the intervention that results in admission to the
hospital, or permanent disability, or is life threatening.
This will include:
 swelling of the face, lips, tongue, the area around the
eyes or other part of the body
 rash, itching, hives, breathlessness or difficult
breathing, wheezing or coughing
 light-headedness, dizziness, changes in levels of
consciousness, hypotension, with or without mild
generalized itching, skin reddening
 signs that blood clots may have formed,
such as sudden severe headache, sudden loss of
coordination, blurred vision or sudden loss of vision,
slurred speech, numbness or tingling in an arm or
leg, painful swelling in the calves or thighs, chest
pain, difficulty breathing, coughing blood
Statistical analysis
Statistical analysis will use intention to treat principles
and per protocol analysis. A mixed model ANCOVA will
be undertaken, adjusting for baseline values of the
dependent variables to determine the difference between
groups for primary and secondary outcomes. In addition,
a responder analysis will be undertaken to determine
clinical significance [65]. Participants who achieve an in-
crease in VISA-G scores greater than the minimal detect-
able change score (10 points) [60] will be categorised as
responders. The difference between the proportions of re-
sponders and non-responders in the four groups will then
be analysed with risk ratios, risk differences and numbers
needed to treat [53]. Participants randomised into the sin-
gle exercise arm will be analysed separately. Where data is
missing, baseline data will be carried forward.
Discussion
This study will be the first randomised controlled trial to
compare the effectiveness of MHT alone, and with the
combination of exercise therapy, to treat pain and dys-
function associated with GTPS. This study has been
pragmatically designed to ensure that interventions im-
plemented in this study can be integrated into policy
and clinical practice if found to be effective in the treat-
ment of GTPS in post-menopausal women. It aims to
minimise bias through methodological features of ran-
domisation, blinding where possible, concealed alloca-
tion and intention to treat analysis.
There are risks with any study involving pharmaco-
logical interventions, however considerable efforts have
been made to minimise these. A transdermal method of
administrating hormones has been chosen as it com-
bines an efficacious use of oestrogen replacement with
the safest route of administration [66]. Additionally it is
the gold standard for menopausal hormone replacement
therapy, as it has a lower risk of venous thromboembolism
than oral administration [67]; it is easily formulated and ti-
trated; and has an additional safety benefit of avoiding the
hepatic ‘first pass’ effect associated with oral administra-
tion, thus avoiding changes in clotting factors and sex
hormone-binding globulin [68].
The validity of GTPS as a clinical entity has been
determined using convergence of validity principles,
previously described by George and Delitto [69], and
diagnostic criteria based on by Fearon et al. [70]. The
convergence of validity principles involves gathering
evidence from multiple sources with differing methodolo-
gies to determine if the underlying constructs are of simi-
lar meaning. Three main principles have been selected for
the current study: expert opinion; biological plausibility;
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and diagnostic tests/strategies for minimising false positive
diagnoses.
The validity of GTPS as a clinical entity is supported
by research on biological plausibility. Pathological fea-
tures of gluteus medius and minimus tendinopathy have
been likened to that of supraspinatus tendinopathy and
subacromial bursitis of the shoulder [1, 71–73]. Anatom-
ically, the gluteus medius tendons inserts onto the lateral
and posterior-superior portion of the greater trochanter
[74], and the gluteus minimus onto the anterior portion
of the greater trochanter and acts as a femoral head sta-
biliser through hip joint range [75]. The positioning of
these tendons is such that loss of the lateral stability
mechanism (frontal plane femoropelvic alignment and
medio-lateral stability in standing) from hip abductor
weakness [76], can cause compression of these struc-
tures and reproduction of lateral hip pain. Similarly, pain
reproduction with passive elongation of the involved
tendons or active contraction of these same tendons is
reported as a clinical feature of gluteal tendinopathy/
GTPS [42]. Clinical tests used to assess for GTPS in the
trial are likely to reveal symptoms associated with one or
both of these mechanisms. Additionally, common subject-
ive clinical findings such as difficulty lying on their side at
night [77, 78] and pain with weight bearing activities
[1, 78, 79] will be identified using the VISA-G
questionnaire.
Due to the difficulties in diagnosing GTPS, there are
aspects of our diagnostic criteria that are likely to im-
prove diagnostic accuracy and minimise false positive
diagnoses. Tendon experts recommend a battery of tests
be used for clinical assessment and interpretation of hip
abductor function [76]. This study will only include par-
ticipants if they score <80 on the VISA-G questionnaire
(a measure of pain and dysfunction associated with the
condition) and have reproduction of lateral hip pain on
a minimum of 3/5 diagnostic clinical tests.
Based on the convergence of this quantitative research,
as well as the expertise of one of the authors (JC) who is
a world-renowned tendon expert, with over 30 years of
clinical experience in the area of tendon structure, func-
tion and dysfunction, the diagnostic criteria used to
identify GTPS in this study have acceptable validity.
Development of the gluteal tendon rehabilitation pro-
gram is based on expert opinion and guided by manage-
ment strategies of other lower limb tendons. Commencing
the program with gluteal isometrics is used as an initial
pain relieving strategy [50] prior to loading with internal
perturbations (toe taps and hip swing). All gluteal exercises
are performed avoiding compression of the gluteal tendons
(no hip adduction/crossing midline), since compression
is thought to induce tendon pathology [80] by altering
mechanotransduction and causing fibrocartilage forma-
tion [81]. Additionally, activities involving hip adduction
including side-lying in bed [77, 78], and weight-bearing
activities (stair climbing, rising from a chair) have been as-
sociated in lateral hip pain [1, 78, 79]. In this program, all
exercises aim at loading the gluteal tendon occur on a sin-
gle leg as double leg exercises allow compensation with
the other leg [82] and inefficient tendon loading. Further-
more, this program focuses on rehabilitation of the kinetic
chain - sequenced physiologic muscle activations that
allow performance of an integrated biomechanical task
[83]. This has been recommended to ensure complete res-
toration of lower leg muscle-tendon function [84]. The
sham exercise program, although activating the same
muscle groups as the intervention, clinically, these exer-
cises are not aimed at strengthening muscle groups or
loading the gluteal tendons.
Study results will be disseminated to the wider health
network by journal publication, and reported back to par-
ticipants via email. The findings of this study will help de-
termine the effectiveness of menopausal hormone therapy
and exercise therapy in post-menopausal women with
GTPS. Additionally it will identify if an exercise program
targeted at loading of the gluteal tendons in addition to
kinetic chain strengthening is more superior to that of a
low load lower limb sham exercise program. The results
of this study aim to help guide medical and allied health
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